Aksaka, E, Emet, M (2012). Complete atrioventricular block due to overdose of pregabalin. American Journal of Emergency Medicine 30, 2101.e1–2101.e4.
Allgulander, C (2010). Novel approaches to treatment of generalized anxiety disorder. Current Opinion in Psychiatry 23, 37–42.
Baldwin, DS, Ajel, K (2007). Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatric Disease and Treatment 3, 185–191.
Ben-Menachem, E (2004). Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 45 (Suppl. 6): 13–18.
Berry, D, Millington, C (2005). Analysis of pregabalin at therapeutic concentrations in human plasma/serum by reversed-phase HPLC. Therapeutic Drug Monitoring 27, 451–456.
Boyle, J, Eriksson, ME, Gribble, L, Gouni, R, Johnsen, S, Coppini, DV, Kerr, D (2012). Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care 35, 2451–2458.
Bucur, M, Jeczmien, P (2011). Pregabalin and libido-case reports. The Open Neuropsychopharmacology Journal 4, 8–9.
Chen, ZR, Irvine, RJ, Somogyi, AA, Bochner, F (1991). Mu receptor binding of some commonly used opioids and their metabolites. Life Sciences 48, 2165–2171.
Dijkstra, BA, Krabbe, PF, De Jong, CA, van der Staak, CP (2008). Prediction of withdrawal symptoms during opioid detoxification. Journal of Opioid Management 4, 311–319.
Dobrea, C, Buoli, M, Arici, C, Camuri, G, Dell’osso, B, Altamura, AC (2012). Tolerability and use in co-administration of pregabalin in affective patients: a 6-month prospective naturalistic study. Expert Opinion on Drug Safety 11, 893–899.
El-Bassel, N, Gilbert, L, Rajah, V (2003). The relationship between drug abuse and sexual performance among women on methadone heightening the risk of sexual intimate violence and HIV. Addictive Behaviors 28, 1385–1403.
European Medicines Agency (2006). Lyrica – scientific discussion, European Medicines Agency, London.
European Monitoring Centre for Drugs and Drug Addiction (2012). Gabapentin and pregabalin: abuse and addiction. Prescrire International 21, 152–154.
Feltner, DE, Crockatt, JG, Dubovsky, SJ, Cohn, CK, Shrivastava, RK, Targum, SD, Liu-Dumaw, M, Carter, CM, Pande, AC (2003). A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. Journal of Clinical Psychopharmacology 23, 240–249.
Filipetto, FA, Zipp, CP, Coren, JS (2010). Potential for pregabalin abuse or diversion after past drug-seeking behaviour. The Journal of the American Osteopathic Association 110, 605–607.
Frame, B, Miller, R, Hutmacher, MM (2009). Joint modeling of dizziness, drowsiness, and dropout associated with pregabalin and placebo treatment of generalized anxiety disorder. Journal of Pharmacokinetics and Pharmacodynamics 36, 565–584.
Graversen, C, Olesen, SS, Olesen, AE, Steimle, K, Farina, D, Wilder-Smith, OH, Bouwense, SA, van Goor, H (2012). The analgesic effect of pregabalin in patients with chronic pain is reflected by changes in pharmaco-EEG spectral indices. British Journal of Clinical Pharmacology 73, 363–372.
Grosshans, M, Mutschler, J, Hermann, D, Klein, O, Dressing, H, Kiefer, F, Mann, K (2010). Pregabalin abuse, dependence, and withdrawal: a case report. American Journal of Psychiatry 167, 869.
Hill, DR, Suman-Chauhan, N, Woodruff, GN (1993). Localization of [3 H]gabapentin to a novel site in rat brain: autoradiographic studies. European Journal of Pharmacology 244, 303–309.
Hitiris, N, Barrett, JA, Brodie, MJ (2006). Erectile dysfunction associated with pregabalin add-on treatment in patients with partial seizures: five case reports. Epilepsy and Behavior 8, 418–421.
Kamel, JT, D’Souza, WJ, Cook, MJ (2010). Severe and disabling constipation: an adverse effect of pregabalin. Epilepsia 51, 1094–1096.
Kapczinski, F, Lima, MS, Souza, JS, Schmitt, R (2003). Antidepressants for generalized anxiety disorder. Cochrane Database of Systematic Reviews 2003, CD003592.
Kavoussi, R (2006). Pregabalin: from molecule to medicine. European Neuropsychopharmacology 16 (Suppl. 2): S128–S133.
Leonhart, M (2005). Schedules of Controlled Substances: Placement of Pregabalin Into Schedule V. Federal Register 70, 43633–43635.
Lenox-Smith, AJ, Reynolds, A (2003). A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. The British Journal of General Practice 53, 772–777.
Li, Z, Taylor, CP, Weber, M, Piechan, J, Prior, F, Bian, F, Cui, M, Hoffman, D, Donevan, S (2011). Pregabalin is a potent and selective ligand for α(2)δ-1 and α(2)δ-2 calcium channel subunits. European Journal of Pharmacology 667, 80–90.
Miljevic, C, Crnobaric, C, Nikolic, S, Lecic-Tosevski, D (2012). A case of pregabalin intoxication. Psychiatriki 23, 162–165.
Montgomery, SA, Tobias, K, Zornberg, GL, Kasper, S, Pande, AC (2006). Efficacy and treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. Journal of Clinical Psychiatry 67, 771–782.
National Institute for Health and Clinical Excellence (2007). Anxiety (amended). Management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. Clinical Guidance 22, April (http://www.nice.org.uk).
Olaizola, I, Ellger, T, Young, P, Bösebeck, F, Evers, S, Kellinghaus, C (2006). Pregabalin-associated acute psychosis and epileptiform EEG-changes. Seizure: The Journal of the British Epilepsy Association 15, 208–210.
Oulis, P, Konstantakopoulos, G, Kouzoupis, AV, Masdrakis, VG, Karakatsanis, NA, Karapoulios, E, Kontoangelos, KA, Papadimitriou, GN (2008 a). Pregabalin in the discontinuation of long-term benzodiazepines’ use. Human Psychopharmacology 23, 337–340.
Oulis, P, Kouzoupis, AV, Koulouris, G, Masdrakis, VG, Kontoangelos, K, Matsoukas, T, Papadimitriou, GN (2008 b). Acute pregabalin reversal of citalopram-induced sexual dysfunction in generalized anxiety disorder. Journal of Clinical Psychopharmacology 28, 362–363.
Page, RL 2nd, Cantu, M, Lindenfeld, J, Hergott, LJ, Lowes, BD (2008). Possible heart failure exacerbation associated with pregabalin: case discussion and literature review. Journal of Cardiovascular Medicine 9, 922–925.
Pande, A, Crockatt, J, Feltner, D, Janney, C, Smith, W, Weisler, R, Londborg, P, Bielski, R, Zimbroff, D, Davidson, J, Liu-Dumaw, M (2003). Pregabalin in generalized anxiety disorder: a placebo-controlled trial. American Journal of Psychiatry 160, 533–540.
Philippsohn, S, Kruger, TH (2012). Persistent genital arousal disorder: successful treatment with duloxetine and pregabalin in two cases. The Journal of Sexual Medicine 9, 213–217.
Pohl, RB, Feltner, DE, Fieve, RR, Pande, AC (2005). Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. Journal of Clinical Psychopharmacology 25, 151–158.
Reedy, SJD, Schwartz, MD (2010). A case series of recreational pregabalin overdose resulting in generalized seizures. Clinical Toxicology 48, 616–617.
Rickels, K, Zaninelli, R, McCafferty, J, Bellew, K, Iyengar, M, Sheehan, D (2003). Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. American Journal of Psychiatry 160, 749–756.
Saddock, VA (2005). Normal human sexuality and sexual dysfunctions. In Kaplan and Sadock’s Comprehensive Textbook of Psychiatry (ed. VA Sadock and BJ Sadock), 8th edn. vol. 1, p. 1902. Baltimore, Lippincott Williams and Wilkins: New York.
Schifano, F, D’Offizi, S, Piccione, M, Corazza, O, Deluca, P, Davey, Z, Di Melchiorre, G, Di Furia, L, Farré, M, Flesland, L, Mannonen, M, Majava, A, Pagani, S, Peltoniemi, T, Siemann, H, Skutle, A, Torrens, M, Pezzolesi, C, van der Kreeft, P, Scherbaum, N (2011). Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychotherapy and Psychosomatics 80, 118–122.
Schwan, S, Sundström, A, Stjernberg, E, Hallberg, E, Hallberg, P (2010). A signal for an abuse liability for pregabalin – results from the Swedish spontaneous adverse drug reaction reporting system. European Journal of Clinical Pharmacology 66, 947–953.
Selak, I (2001). Pregabalin (Pfizer). Current Opinion in Investigational Drugs 2, 828–834.
Skopp, G, Zimmer, G (2012). Pregabalin – a drug with abuse potential? Archiv für Kriminologie 229, 44–54.
Spiller, HA, Bratcher, R, Griffith, JR (2008). Pregabalin overdose with benign outcome. Clinical Toxicology (Philadilphia) 46, 917.
Taylor, D, Paton, C, Kapur, S (2009). The Maudsley Prescribing Guidelines, 10th edn. Informa Healthcare: London, pp. 457–461.
Yargic, I, Ozdemiroglu, FA (2011). Pregabalin abuse: a case report. Bulletin of Clinical Psychopharmachology 21, 64–66.
Zaccara, G, Gangemi, P, Perucca, P, Specchio, L (2011). The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia 52, 826–836.
Zacny, JP, Paice, JA, Coalson, DW (2012). Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers. Pharmacology. Biochemistry and Behavior 100, 560–565.
Zhou, Q, Zheng, J, Yu, L, Jia, X (2012). Pregabalin monotherapy for epilepsy. Cochrane Database of Systematic Reviews 17, CD009429.